Aaron Sato Email & Phone Number

Lebanon, New Hampshire, US

• Guide marketing strategies and engage with potential partners across various therapeutic approaches, including Adimab's technology related to monoclonal and multispecific antibody discovery and optimization, T-cell.
• Help lead internal cross-functional efforts to develop competitive intelligence, perform internal and external technology analysis, and drive external technical engagement with drug development companies, key opinion.

Leads virtual company focused on novel serine proteinase inhibitors discovery, engineering, and development to treat rare diseases such as alpha-1-antitrypsin (AAT) deficiency. Lead development candidate is an engineered long-acting AAT albumin fusion, resistant to lung oxidation and loop-sheet polymerization.Impact: Discovered 1) protein-based kunitz.

South San Francisco, California, US

• Provides the pharma and biotechnology industry with an end-to-end antibody discovery and optimization solution utilizing our proprietary DNA writing technology, proprietary mouse platform, and cutting-edge machine.
• Led Biopharma 70+ member team formation from ground-up. Developed new high performing leaders.
• Generated $20M+ revenue/year for the business.

South San Francisco, California, US

Drives new custom Biopharma-inspired product creation that stem from Twist’s DNA synthesis platform, e.g. HT lgG and combinatorial assembly librariesLeads new Biopharma division product initiatives, Biopharma pipeline efforts to create new internal preclinical leads for out-licensing and spin-out efforts (interim scientific leader of new Twist spin-outs.

South San Francisco, California, US

• Provides biotechnology industry with end-to-end antibody discovery solution using proprietary DNA writing technology to create oligo pools, genes, and synthetic libraries.Senior management team member; routinely.
• Led Biopharma 50+ member team formation from ground-up. Developed new high performing leaders.
• Generated $10M+ revenue/year for business.
• Discovered: 1) panel of antibody leads against array of targets; completed first lead option deal in 2022; 2) first-in-class anti-GPCR antibody antagonists against GLP1R and ADORA2A; best-in-class anti-SARS-CoV-2.

• Global biologics provider for protein engineering, antibody drug development, biomanufacturing, integrated solutions. (Now part of Curia.)Oversaw the California Antibody Center (50 scientists, 15 PhDs) to discover.
• Generated $50M+ revenue/year for core business.
• Improved CRO services to partners by elevating staff scientific expertise.
• Helped start-up and small companies discover/generate their own biologics to treat patients.

South San Francisco, California, US

• Directed discovery research functions for biopharmaceutical startup founded by Stanford University scientists, Drs. Chris Garcia, Roel Nusse, and Calvin Kuo. Harnessed key signaling pathways to identify regenerative.
• Hired the team that discovered key antibody leads and established foundational IP for company formation.
• Set up the antibody platform that found anti-LRP5/6 and anti-Fzd antibodies to create novel Wnt-mimetic bispecifics.
• Established company’s core IP technology.

South San Francisco, California, US

• Senior leadership team member, JSC member for major partner collaborations (Celgene immune-oncology bispecifics, Merck Serono ADCs); project team leader for internal technology development and novel immune-oncology.
• Anti-tumor antigen antibodies (receptor agonists/antagonists)
• Bispecific T-cell engagers (Immuno-oncology, recruit T-cells to tumor)
• Dual checkpoint antagonist bispecifics (Immuno-oncology, e.g. block both PD1/CTLA4)
• Antibody drug conjugates (ADCs) to over-expressed tumor antigens
• VaccinesImpact:

Redwood City, CA, US

• Led antibody lead discovery and antibody engineering, focused on cancer stem cell targets. Project team leader for preclinical antibody leads. Managed internal research and process development and timeline.
• Discovered: several antibodies that entered clinical development (anti-Notch2/3, anti-Fzd1/2/5/7/8, anti-VEGF/DLL4 bispecific). Team leader for all studies that led to IND.
• Created: several antibody discovery platforms in phage and mammalian display.

Burlington, MA, US

Led antibody, peptide, and small protein discovery through proprietary phage display technology. Sr. Director, Lead Discovery: Oversaw funded or co-development collaborations with major pharmaceutical (Pfizer), imaging (Bracco, EPIX Pharmaceuticals), and biotechnology partners (Biogen Idec, Amgen, Inhibitex, Syntonix, Tanox, Genzyme, Human Genome.

Doctor Of Philosophy - Phd, Biological Chemistry (Course V)

Bachelor Of Science - Bs, Chemistry